By Abigail Townsend
Date: Thursday 16 May 2024
(Sharecast News) - AstraZeneca said on Thursday that its investigative drug sipavibart had shown positive results in preventing Covid-19 in vulnerable patients.
The FTSE 100 drugs firm said the phase III pre-exposure prophylaxis trial had met both its primary endpoints, of showing a relative risk reduction of Covid caused by different...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news